Monday, May 20, 2013 Last update: 12:04 AM
Company Tech News as it Breaks
Biotech/Biomedical/Health News
Monday, December 6, 2010
- 2010 Human Research Protection Award Recipients Announced --- BETHESDA, Md., Dec. 6, 2010Posted at 6:50 AMAwards for Excellence in Human Research Protection for 2010 were announced today by Dr. Peter G. Goldschmidt, President and Founder of the Health Improvement Institute. Recipients of an Annual Award included: -- Best practice: Human Research Protection Office, Washington University in St. Louis (St. Louis, MO), Community Engaged Research Program. The objective of this program is to support research that addresses ... read more
- Network Solutions® Introduces Universal Gift Registry Solution from MyRegistry.com® --- FORT LEE, N.J. and HERNDON, Va., Dec. 6, 2010Posted at 6:45 AMMyRegistry.com®, the leader in online gift registry technology, today announced the integration of its Universal Gift Registry solution with the Network Solutions® nsCommerceSpace(TM) platform. Now, when Networks Solutions ecommerce merchants place the highly customizable MyRegistry Universal Gift Registry widget on their product pages, their customers can easily add items to a one-stop registry. This solution benefits ecommerce merchants, their customers, and the buyers who visit MyRegistry.com to select a gift. "We are excited to make our Universal Gift Registry solution available ... read more
- Entravision Communications Corporation to Present at Two Upcoming Investor Conferences --- SANTA MONICA, Calif., Dec. 6, 2010Posted at 6:30 AMEntravision Communications Corporation (NYSE: EVC) announced today that Christopher T. Young, Executive Vice President, Chief Financial Officer and Treasurer, will be presenting at the UBS 38th Annual Media & Communications Conference in New York, NY at 1:30 p.m. EST on Tuesday, December 7, 2010, and the Wedbush Morgan Securities 11th Annual MAC Conference in Santa Monica, CA at 1:40 p.m. EST on Wednesday, December 8, 2010. The presentation at the UBS 38th Annual Media & Communications Conference will be made available ... read more
- XIAFLEX® Effective in Nonsurgically Treating MP and PIP Joints with Dupuytren's Contractures in Second Pivotal Study --- MALVERN, Pa., Dec. 6, 2010Posted at 6:30 AMAuxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company, today announced that The Journal of Hand Surgery (JHS) has published in its December online edition the Company's pivotal CORD II phase III clinical trial of XIAFLEX® (collagenase clostridium histolyticum), a novel, first-in-class biologic for the nonsurgical treatment of adult Dupuytren's contracture patients with a palpable cord. The CORD II study is the second pivotal clinical trial examining the treatment of Dupuytren's contracture with XIAFLEX. Treatment with XIAFLEX significantly ... read more
-
Posted at 6:30 AMZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that new preclinical data on the novel mechanism of its organic arsenic darinaparsin (ZIO-101) in various lymphoma models were presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando Florida. Andrew M ... read more
- Longer-term Phase III data show Novartis drug Tasigna® continues to surpass Gleevec® in slowing disease progression in patients with newly diagnosed CML --- EAST HANOVER, N.J., Dec. 6, 2010Posted at 6:09 AMEAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the disease -- 24-month analysis confirms Tasigna induces deeper and more durable cytogenetic and molecular responses -- Tasigna now approved ... read more
- YM BioSciences notice of analyst meeting and conference call --- ORLANDO, Dec. 6Posted at 6:00 AMCompany to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) announced that it will hold an analyst meeting and conference call today at 12:30pm ET to discuss the interim results from the first 60 patients enrolled in the 140 patient Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, in myelofibrosis. An oral presentation of the interim ... read more
- UniversalBusinessListing.org and Locationary Create Real-Time Business Profile Broadcast System for Publishers --- CHARLOTTE, N.C., Dec. 6, 2010Posted at 6:00 AMUniversalBusinessListing.org (UBL) and Locationary today announced a strategic partnership to manage and distribute business profile data free to online and mobile directory publishers. The platform currently comprises 22 million enhanced business listings that publishers can access to power their online search services. In addition to serving publishers' needs for rich business listings content in a uniform format, the partnership will enable businesses to provide more detailed and up-to-date information to potential customers who are searching online. This is important, because profile ... read more
- VIVUS Announces Positive Results From Long-Term Phase 3 Study of Avanafil in Erectile Dysfunction --- MOUNTAIN VIEW, Calif., Dec. 6, 2010Posted at 6:00 AMVIVUS, Inc. (Nasdaq: VVUS) today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF). In the study, patients treated with avanafil who attempted sexual intercourse (SEP3) within the first 15 ... read more
- Champions Biotechnology Announces Master Service Agreement with Teva Pharmaceutical Industries, Ltd. for the Evaluation of a Novel Oncology Compound --- BALTIMORE, Dec. 6, 2010Posted at 6:00 AMChampions Biotechnology, Inc. (OTC Bulletin Board: CSBR), an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft(TM) platform. Anti-angiogenic compounds are designed to work by blocking the tumor's blood supply. There are multiple approved and experimental anti-angiogenic compounds for colorectal, breast, and lung cancer. ... read more
- Astera Delivers Real-Time Data Integration for Better Business Intelligence --- ENCINO, Calif., Dec. 6, 2010Posted at 6:00 AMAstera Software, a leading provider of data integration solutions through its Centerprise Data Integration platform, announces the beta version of Centerprise Data Integration Real-Time Edition (RTE). (Logo: http://photos.prnewswire.com/prnh/20101102/LA92801LOGO) "Real-time integration enables companies to make critical up-to-the-minute data available to decision makers, improve customer service by ensuring consistent data across operational systems, and enhance operational efficiencies by building tight integration between business applications," says Ibrahim Surani, CEO of Astera Software. "When compared to the traditional approach of hand-coding integration, Centerprise delivers substantial ... read more
- Attunity Receives Two Awards by SQL Server Magazine for Best Business Intelligence (BI) Software --- BURLINGTON, Mass., Dec. 6, 2010Posted at 6:00 AMAttunity Ltd. (OTC Bulletin Board: ATTUF), a leading provider of real-time data integration and event capture software, announced today that its Attunity SQL Server-CDC for SSIS data replication software was recognized in the Best BI/Reporting product category, winning the bronze medal for two SQL Server Magazine awards, the "2010 Community Choice Award" and the "2010 Editors' Best Award". The 2010 winners will appear in the December issue of SQL Server Magazine, and will showcase the companies and products chosen in ... read more
- Emergent BioSolutions Presents Positive Data from Its TRU-016 Program at American Society of Hematology Meeting --- ROCKVILLE, Md.Posted at 6:00 AMEmergent BioSolutions Inc. (NYSE: EBS) today announced the presentation of positive data from a Phase I dose escalation study of TRU-016 (Protocol 16007) at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In an oral presentation given yesterday, results from ... read more
- Fraunhofer USA CMB Initiates Phase I Clinical Trial for Avian (H5N1) Influenza Vaccine --- NEWARK, Del.Posted at 6:00 AMFraunhofer USA Center for Molecular Biotechnology (CMB) announced today it has received approval from the Food and Drug Administration to proceed with the first human clinical trial of plant-produced H5N1 influenza vaccine. Fraunhofer CMB’s new, plant-based transient expression system ... read more
- PROCHIEVE 8% Vaginal Progesterone Gel Achieves Primary Endpoint in Phase III Study to Reduce Risk of Preterm Birth --- LIVINGSTON, N.J. and MORRISTOWN, N.J., Dec. 6, 2010Posted at 5:55 AMColumbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced positive top-line results from the PREGNANT Study, a large, global Phase III clinical trial evaluating PROCHIEVE® 8% vaginal progesterone gel to reduce the risk of preterm birth in women with a short cervical length as measured by transvaginal ultrasound at mid-pregnancy. The administration of PROCHIEVE 8% vaginal progesterone gel was associated with a statistically significant reduction in the rate of preterm birth at less than or equal to ... read more
- Rainmaker Renews and Expands Agreement with Global Software and Services Client for Telesales --- CAMPBELL, Calif., Dec. 6, 2010Posted at 5:30 AMRainmaker Systems, Inc. (Nasdaq: RMKR), a leading global provider of ecommerce solutions and telesales services that drive more revenue for clients and their channel partners, today announced a one-year renewal of its agreement with its global software and services client for telesales and an expansion that doubles the size of the current program. Under the agreement, Rainmaker will manage all sales leads in North America for this client, providing inbound customer response management and outbound telemarketing services. Rainmaker CEO Michael Silton ... read more
- Purdue Pharma L.P. Re-launches Partners Against Pain Website --- STAMFORD, Conn., Dec. 6, 2010Posted at 5:00 AMPurdue Pharma L.P. unveiled an enhanced version of its popular educational website www.PartnersAgainstPain.com, making it is easier for healthcare professionals, people with pain and their caregivers to access valuable pain management information, resources and tools. For more than 17 years, the Partners Against Pain program has been offering support to help improve the quality of pain management for individuals touched by pain. (Photo: http://photos.prnewswire.com/prnh/20100921/NY67262 ) In addition to information on medical conditions that cause pain, the enhanced site features customized sections for ... read more
- Radware Helps SK Group Support Next-Generation Unified Communications Platform --- MAHWAH, N.J., Dec. 6, 2010Posted at 4:30 AMRadware (Nasdaq: RDWR), a leading provider of integrated application delivery solutions for business-smart networking, today announced that SK C&C, a leading IT service provider in Korea, has successfully deployed Alteon® 5412 application switches to build a robust, uninterrupted web portal service and reduce total cost of ownership for the SK Group. With more than 30,000 employees in 113 offices worldwide, SK Group was faced with a challenge to find a single platform that would allow for seamless and effective internal communications ... read more
- Integrated Medical Systems' Technology Recognized as Qualified Therapeutic Discovery --- SIGNAL HILL, Calif., Dec. 6, 2010Posted at 4:00 AMThe medical technology developed by Integrated Medical Systems, Inc., has been recognized by the U.S. Department of Health and Human Services and the U.S. Treasury Department as a "qualified therapeutic discovery." The designation earns the company a grant to off-set its development efforts. The Qualifying Therapeutic Discovery Project designation and grant is provided for under the Patient Protection and Affordable Care Act of 2010. The Act set aside $1 billion for projects that show a reasonable potential to result ... read more
-
Posted at 3:30 AMNEW YORK, NY -- (Marketwire) -- 12/06/10 -- Only one in five people in the EU Big 5 diagnosed with atrial fibrillation (AF) who are at high risk for stroke are taking prophylactic Coumadin/warfarin, despite current clinical guides that recommend its use in high-risk patients, according to research conducted by Kantar Health. Kantar Health presented its findings in a poster at the 13th ISPOR (International Society for Pharmacoeconomic and Outcomes Research) European Conference in November in Prague, Czech ... read more
